Barclays’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-97,509
| Closed | -$399K | – | 5497 |
|
|
2022
Q1 | $399K | Sell |
97,509
-185,823
| -66% | -$674K | ﹤0.01% | 3040 |
|
|
2021
Q4 | $1.01M | Buy |
283,332
+117,863
| +71% | +$412K | ﹤0.01% | 2829 |
|
|
2021
Q3 | $602K | Buy |
165,469
+143,738
| +661% | +$581K | ﹤0.01% | 3091 |
|
|
2021
Q2 | $96K | Sell |
21,731
-166,206
| -88% | -$677K | ﹤0.01% | 3858 |
|
|
2021
Q1 | $772K | Buy |
187,937
+125,078
| +199% | +$542K | ﹤0.01% | 2930 |
|
|
2020
Q4 | $251K | Sell |
62,859
-22,361
| -26% | -$72.3K | ﹤0.01% | 3639 |
|
|
2020
Q3 | $230K | Sell |
85,220
-14,994
| -15% | -$41.5K | ﹤0.01% | 3756 |
|
|
2020
Q2 | $275K | Buy |
100,214
+36,707
| +58% | +$102K | ﹤0.01% | 3821 |
|
|
2020
Q1 | $150K | Sell |
63,507
-127,479
| -67% | -$434K | ﹤0.01% | 4506 |
|
|
2019
Q4 | $897K | Buy |
190,986
+90,830
| +91% | +$372K | ﹤0.01% | 3771 |
|
|
2019
Q3 | $335K | Sell |
100,156
-24,115
| -19% | -$79.4K | ﹤0.01% | 4576 |
|
|
2019
Q2 | $409K | Buy |
124,271
+17,137
| +16% | +$49.6K | ﹤0.01% | 4508 |
|
|
2019
Q1 | $325K | Buy |
107,134
+73,970
| +223% | +$240K | ﹤0.01% | 4463 |
|
|
2018
Q4 | $90K | Sell |
33,164
-55,774
| -63% | -$184K | ﹤0.01% | 5115 |
|
|
2018
Q3 | $299K | Buy |
88,938
+58,366
| +191% | +$180K | ﹤0.01% | 4687 |
|
|
2018
Q2 | $80K | Sell |
30,572
-19,403
| -39% | -$48.3K | ﹤0.01% | 5387 |
|
|
2018
Q1 | $109K | Buy |
49,975
+3,224
| +7% | +$7.26K | ﹤0.01% | 5321 |
|
|
2017
Q4 | $93K | Sell |
46,751
-89,587
| -66% | -$195K | ﹤0.01% | 5299 |
|
|
2017
Q3 | $442K | Buy |
136,338
+105,644
| +344% | +$326K | ﹤0.01% | 3744 |
|
|
2017
Q2 | $98K | Buy |
30,694
+2,030
| +7% | +$5.75K | ﹤0.01% | 4930 |
|
|
2017
Q1 | $82K | Buy |
28,664
+18,864
| +192% | +$45.4K | ﹤0.01% | 5034 |
|
|
2016
Q4 | $23K | Buy |
+9,800
| New | +$18.7K | ﹤0.01% | 5567 |
|
|
2016
Q3 | – | Sell |
-18,125
| Closed | -$19K | – | 6884 |
|
|
2016
Q2 | $19K | Buy |
+18,125
| New | +$17.5K | ﹤0.01% | 5297 |
|
|
2015
Q4 | – | Sell |
-809
| Closed | -$1K | – | 6778 |
|
|
2015
Q3 | $1K | Sell |
809
-2,162
| -73% | -$4.24K | ﹤0.01% | 6652 |
|
|
2015
Q2 | $6K | Sell |
2,971
-31,338
| -91% | -$76K | ﹤0.01% | 6384 |
|
|
2015
Q1 | $69K | Buy |
34,309
+27,660
| +416% | +$70.2K | ﹤0.01% | 5079 |
|
|
2014
Q4 | $13K | Buy |
6,649
+2,608
| +65% | +$5.86K | ﹤0.01% | 6588 |
|
|
2014
Q3 | $4K | Buy |
4,041
+1,959
| +94% | +$4.27K | ﹤0.01% | 7268 |
|
|
2014
Q2 | $4K | Sell |
2,082
-2,527
| -55% | -$7.61K | ﹤0.01% | 7222 |
|
|
2014
Q1 | $14K | Sell |
4,609
-1,677
| -27% | -$7.44K | ﹤0.01% | 6781 |
|
|
2013
Q4 | $25K | Buy |
6,286
+2,061
| +49% | +$8.4K | ﹤0.01% | 6587 |
|
|
2013
Q3 | $17K | Sell |
4,225
-1,606
| -28% | -$7.01K | ﹤0.01% | 6597 |
|
|
2013
Q2 | $24K | Buy |
+5,831
| New | +$22.5K | ﹤0.01% | 6752 |
|
Other funds holding ATRS
Barclays's ATRS Position: Q2 2022 in Review
Barclays sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 97,509 shares — an estimated $399K sold.
Barclays first reported a position in ATRS in Q2 2013 and held it in 33 quarters. The position peaked at $1.01M in Q4 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Barclays reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Barclays sold 97,509 Antares Pharma, Inc. shares in Q2 2022, an estimated $399K.
- Barclays first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 33 quarters.
- Barclays's Antares Pharma, Inc. position peaked at $1.01M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.